What's Happening?
MaaT Pharma, a biotechnology company focused on microbiome therapies, has encountered a setback in its application for conditional marketing authorization of MaaT013 (Xervyteg®) for treating acute Graft-versus-Host Disease (aGvHD). The Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a 'negative trend' opinion following an oral explanation session. Despite this, MaaT Pharma plans to request a re-examination of the application, a standard procedure that allows for a new independent scientific assessment. The company remains optimistic about the potential of MaaT013 to address unmet medical needs in aGvHD patients and is committed to working with the EMA to advance the application. MaaT013 is supported by clinical data from the pivotal ARES study and real-world data from an Early Access Program active in 13 countries.
Why It's Important?
The outcome of this regulatory process is crucial for MaaT Pharma as it seeks to introduce a novel treatment for aGvHD, a condition with significant morbidity and mortality. Approval of MaaT013 could provide a new therapeutic option for patients who are resistant to current treatments, such as systemic steroids and ruxolitinib. The decision also impacts the company's financial strategy, as it has taken measures to extend its financial visibility to cover upcoming regulatory milestones. The broader significance lies in the potential for microbiome-based therapies to transform treatment paradigms in oncology, offering new hope for patients with limited options.
What's Next?
MaaT Pharma will proceed with the re-examination process, which involves a new review by different CHMP reviewers. This process is expected to take up to 60 days following the company's request. The outcome will determine whether MaaT013 can proceed to market under the Conditional Marketing Authorization pathway, which allows earlier access to medicines addressing unmet needs. The company will continue to engage with the EMA and the hematology community to support the application and expand patient access.
